Recordati S.p.a. · MIL:REC
Recordati — J.P. Morgan Healthcare Conference 2024
12 slides from Recordati's conference presentation, Jan 10, 2024
Slide 1: Recordati: Best in Class Value Creator
RECORDATI: BEST IN CLASS VALUE CREATOR J.P. Morgan Healthcare Conference 2024 San Francisco, January 10
Slide 2: Company Declarations, Disclaimers and Profile
COMPANY DECLARATIONS, DISCLAIMERS AND PROFILE Statements contained in this presentation, other than historical facts, are “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on
Slide 3: Unique and Diversified Global Player in Rare Diseases and European Partner of Choice
UNIQUE AND DIVERSIFIED GLOBAL PLAYER IN RARE DISEASES AND EUROPEAN PARTNER OF CHOICE IN SPECIALTY PHARMA RECORDATI IN NUMBERS EMPLOYEES MARKETS Specialty & > 4,300 ~150 Primary Care (3) 68% of Revenue REVENUE (1) EBITDA (1) EBITDA margin 33.2% 2,050 - 2,090 750 -770 ~12% vs PY margin ~37% ADJ. NET I
Slide 4: Delivering High Single Digit Growth, Consistently on Plan, with Average ROIC of 15-20%
DELIVERING HIGH SINGLE DIGIT GROWTH, CONSISTENTLY ON PLAN, WITH AVERAGE ROIC(1) OF 15-20% OVER LAST DECADE Group Revenue 2013-2025 - actual and guidance > 2,400(4) million Euro High end of CAGR +7.8% 2,050 – 2,090(3) 1,853 Double digit 1,580 1,482 1,449 growth 1,352 1,288 1,154 1,048 942 987 Mid-sin
Slide 5: Proven and Sustainable Business Model
PROVEN AND SUSTAINABLE BUSINESS MODEL Unique combination of resilient and cash flow generative branded Specialty & Primary Care business (RX, OTC) alongside a high growth global Rare disease business (US now Group’s largest unit) Best-in-class financial profile with consistent track record of growth
Slide 6: Three Drivers of Growth
THREE DRIVERS OF GROWTH 1 2 3 TARGETED ORGANIC BD / M&A INNOVATION SPECIALTY Branded portfolio of flagship RX / Acquisition and licensing of OTC products, driven by focused European mature promotion- & Line extensions on key OTC promotion and positive underlying sensitive products and near PRIMARY
Slide 7: The European Partner of Choice
THE EUROPEAN PARTNER OF CHOICE Recordati Specialty & Primary Care Strong organic growth ahead of relevant markets… …driven by commercial excellence Pharmaceutical Revenue (1) 9M 2023 vs 9M 2022 • Fully integrated regional player with direct presence in 30+ countries, having significant scope and sca
Slide 8: A Global Rare Diseases Business
A GLOBAL RARE DISEASES BUSINESS Recordati Rare Diseases Double-digit growth driven by Endo and Onco… …and by patient and physician awareness Revenue 9M 2023 vs 9M 2022 million Euro • One of the few truly global rare diseases businesses, with direct + 23.5% presence in key geographies: North America,
Slide 9: Rare Endo and Onco Portfolio Positioned for Strong Growth in Mid-Long Term
RARE ENDO AND ONCO PORTFOLIO POSITIONED FOR STRONG GROWTH IN MID-LONG TERM Key drivers ENDOCRINOLOGY • Isturisa(2) increased patient uptake, leveraging long-term efficacy / safety Revenue ~500-550 data and maximizing treatment adherence, with also US label extension million Euro 300-340 to Cushing S
Slide 10: Accretive and Growth BD / M&A to Complement Organic Growth
ACCRETIVE AND GROWTH BD / M&A TO COMPLEMENT ORGANIC GROWTH Long track record of successful execution, with fast and effective integration Specialty & Primary Care • Germany OTC portfolio • Ex-US/China • Dentosan • Italchimici rights to Ledaga Rare Diseases • Farma Projekt • Vitaros • Pro Farma • Cys
Slide 11: Clear Value Proposition, Well Positioned for Continued Success
CLEAR VALUE PROPOSITION, WELL POSITIONED FOR CONTINUED SUCCESS Drive organic growth of Sustain high level of Pursue targeted Maintain clear capital diversified business profitability pipeline opportunities allocation policy Strong underling volume Progressive Maintain sector leading Targeted clinica
Slide 12: NS RECORDATI
NS RECORDATI